Clinical Trials on Chronic Back Pain in China

Total 3475 results

Pfizer
Arena is a wholly owned subsidiary of Pfizer

Completed

Oral Etrasimod Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis in Adult Japanese Participants (ELEVATE UC 40 JAPAN)

Ulcerative Colitis

Japan
National Cancer Centre, Singapore
University of Sydney; Australasian Gastro-Intestinal Trials Group; INDOX Cancer...

Active, not recruiting

Aspirin for Dukes C and High Risk Dukes B Colorectal Cancers (ASCOLT)

Colorectal Cancer

Australia, Saudi Arabia, India, China, Malaysia, Korea, Republic of, Singapore, Indonesia, New Zealand, Sri Lanka
Suzhou Connect Biopharmaceuticals, Ltd.

Completed

A Study Assessing the Efficacy and Safety of CBP-307 in Subjects With Moderate to Severe Ulcerative Colitis (UC)

Moderate to Severe Ulcerative Colitis

United States, China, Pakistan, Ukraine
National Cancer Center Hospital East
Alpha-A, Inc.

Recruiting

Initial Attack on Latent Metastasis Using TAS-102 for ct DNA Identified Colorectal Cancer Patients After Curative Resection (ALTAIR)

Colorectal Neoplasms | Circulating Tumor DNA | Trifluridine and Tipiracil

Japan, Taiwan
NRG Oncology
National Cancer Institute (NCI)

Active, not recruiting

Circulating Tumor DNA Testing in Predicting Treatment for Patients With Stage IIA Colon Cancer After Surgery

Colon Adenocarcinoma | Stage IIA Colon Cancer AJCC v8

United States, Canada, Puerto Rico
Daiichi Sankyo
AstraZeneca

Active, not recruiting

Trastuzumab Deruxtecan in Participants With HER2-overexpressing Advanced or Metastatic Colorectal Cancer (DESTINY-CRC02)

Advanced Colorectal Cancer

Korea, Republic of, United States, Taiwan, Belgium, Spain, Japan, United Kingdom, France, Italy, Australia
Pfizer
Arena is a wholly owned subsidiary of Pfizer

Recruiting

A Study to Evaluate Etrasimod Treatment in Adolescents With Ulcerative Colitis

Ulcerative Colitis

United States, Spain, Japan, Belgium, Austria, Poland
Boehringer Ingelheim

Completed

BI655130 (SPESOLIMAB) Induction Treatment in Patients With Moderate-to-severe Ulcerative Colitis

Colitis, Ulcerative

Canada, United States, Spain, United Kingdom, Belgium, Germany, Italy, Japan, Korea, Republic of, Poland, Russian Federation, Austria
EA Pharma Co., Ltd.

Completed

Study of E6007 in Japanese Patients With Moderate Active Ulcerative Colitis

Moderate Active Ulcerative Colitis

Japan
Sanofi

Recruiting

Dose-finding Study of SAR443122 in Adult Participants With Ulcerative Colitis (RESOLUTE)

Colitis Ulcerative

Argentina, Chile, United States, China, Czechia, France, Germany, Hungary, India, Italy, Japan, Mexico, Netherlands, Poland, Spain, United Kingdom
AstraZeneca

Recruiting

First in Human Study of AZD9592 in Solid Tumors (EGRET)

Head and Neck Neoplasms | Colorectal Neoplasms | Advanced Solid Tumours | Carcinoma Non-small Cell Lung

United States, China, Korea, Republic of, Spain, Australia, Japan, Malaysia, Taiwan, Canada, France, Italy
Janssen Research & Development, LLC

Recruiting

A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer (OrigAMI-1)

Advanced or Metastatic Colorectal Cancer

United States, Korea, Republic of, Taiwan, Malaysia, Germany, Italy, Spain, Belgium, Canada, Puerto Rico, China
Bristol-Myers Squibb

Completed

A Study to Evaluate the Long-term Safety and Efficacy of Deucravacitinib in Participants With Crohn's Disease or Ulcerative Colitis

Crohn Disease | Ulcerative Colitis

Romania, Italy, United States, Australia, Canada, China, Germany, Hungary, Japan, Netherlands, Poland, Portugal, Russian Federation, Spain, Taiwan, United Kingdom
Pfizer

Completed

Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer

Colorectal Cancer

United States, Canada, Australia, Germany, Japan, Netherlands, Spain, France, Belgium, Korea, Republic of, Italy, Norway
Bristol-Myers Squibb

Active, not recruiting

A Study of Nivolumab-relatlimab Fixed-dose Combination Versus Regorafenib or TAS-102 in Participants With Later-lines of Metastatic Colorectal Cancer (RELATIVITY-123)

Colorectal Neoplasms

Italy, Canada, Korea, Republic of, Sweden, United States, Argentina, Australia, Austria, Belgium, Chile, China, Czechia, France, Germany, Japan, Netherlands, Poland, Puerto Rico, Singapore, Spain, Switzerland, Taiwan
Takeda

Completed

Sub-optimal Response to Anti-Tumor Necrosis Factor's in Inflammatory Bowel Disease in Emerging Markets

Inflammatory Bowel Diseases | Crohn Disease | Colitis, Ulcerative

China, Korea, Republic of, Taiwan, Russian Federation, Turkey, Argentina, Colombia, Mexico, Saudi Arabia, Singapore
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd

Completed

An Investigational Immunotherapy Study of Nivolumab With Standard of Care Therapy vs Standard of Care Therapy for First-Line Treatment of Colorectal Cancer That Has Spread (CheckMate 9X8)

Colorectal Cancer

United States, Puerto Rico, Canada, Japan, Spain
AbbVie

Recruiting

An Observational Study to Assess Change in Disease Activity and Adverse Events of Rinvoq in Adult Participants With Moderate to Severe Ulcerative Colitis (UC) in Japan

Ulcerative Colitis

Japan
Pfizer

Completed

A Study Combining FOLFOX or FOLFIRI With AG-013736 or Bevacizumab (Avastin) in Patients With Metastatic Colorectal Cancer After Failure Of One First Line Regimen

Colorectal Neoplasms

Canada, United States, France, Poland, Italy, Spain, Korea, Republic of, Japan
Seagen Inc.
Merck Sharp & Dohme LLC

Recruiting

A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer (MOUNTAINEER-03)

Colorectal Neoplasms

United States, Canada, Italy, Argentina, United Kingdom, China, Japan, Belgium, France, Korea, Republic of, Spain, Taiwan, Brazil, Ireland, Netherlands, Australia, Slovakia, Chile, Poland, Norway, Switzerland, Austria, Germany, Portugal, Gree... and more
Biogen

Recruiting

A Study to Assess the Efficacy and Safety of BIIB059 (Litifilimab) in Participants With Active Subacute Cutaneous Lupus Erythematosus (SCLE) and/or Chronic Cutaneous Lupus Erythematosus (CCLE) With or Without Systemic Manifestations and Refractory and/or Intolerant to Antimalarial Therapy (AMETHYST)

Subacute Cutaneous Lupus Erythematosus | Chronic Cutaneous Lupus Erythematosus

United States, Italy, Korea, Republic of, Taiwan, Argentina, Chile, Spain, Canada, Serbia, France, Germany, Japan, Brazil, United Kingdom, Bulgaria, Portugal, Switzerland, Philippines, Saudi Arabia, Sweden, Mexico, Poland, Hungary, Puerto... and more
Daiichi Sankyo, Inc.

Terminated

A Study to Evaluate U3-1402 in Subjects With Advanced or Metastatic Colorectal Cancer

Metastatic Colorectal Cancer

United States, Spain, Belgium, Japan, France, United Kingdom, Italy, Poland
Reistone Biopharma Company Limited

Recruiting

A Phase 3 Study to Investigate the Efficacy and Safety of SHR0302 With Moderately to Severely Active Ulcerative Colitis

Ulcerative Colitis

China, United States, Georgia, Poland, Ukraine
Takeda

Recruiting

A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Ulcerative Colitis (UC)

Colitis, Ulcerative

United States, Israel, Canada, Italy, United Kingdom, Hungary, Japan, Australia, China, Greece, Belgium, Croatia, Korea, Republic of, Poland, Czechia
UCB BIOSCIENCES, Inc.

Completed

Safety and Efficacy of Lacosamide as Additional Therapy in Patients Suffering From Epileptic Tonic-Clonic Seizures (VALUE)

Epilepsy

United States, Australia, Brazil, Bulgaria, China, Czechia, France, Germany, Hungary, Israel, Italy, Japan, Korea, Republic of, Mexico, Poland, Portugal, Romania, Russian Federation, Slovakia, Spain, Taiwan
Pierre Fabre Medicament
Pfizer; Merck KGaA, Darmstadt, Germany; Ono Pharmaceutical Co. Ltd

Completed

Encorafenib, Binimetinib and Cetuximab in Subjects With Previously Untreated BRAF-mutant ColoRectal Cancer (ANCHOR-CRC)

BRAF V600E-mutant Metastatic Colorectal Cancer

France, Italy, United States, Spain, United Kingdom, Belgium, Austria, Japan, Netherlands
Novartis Pharmaceuticals

Recruiting

Study of HRO761 Alone or in Combination in Cancer Patients With Specific DNA Alterations Called Microsatellite Instability or Mismatch Repair Deficiency.

MSIhi or dMMR Advanced Unresectable or Metastatic Solid Tumors, Including Colorectal Cancers

Japan, Italy, Spain, Singapore, Belgium, Germany, Korea, Republic of, Sweden, Taiwan, France, Israel, Norway, United States
Eli Lilly and Company

Recruiting

A Study of Mirikizumab (LY3074828) in Pediatric Participants With Moderately to Severely or Active Ulcerative Colitis (SHINE-2)

Ulcerative Colitis

United States, Canada, Poland, Japan, Belgium, Israel, Portugal, Korea, Republic of, France, Australia, Italy, Netherlands, Germany, United Kingdom
Pfizer

Completed

A Study Evaluating The Efficacy And Safety Of CP-690,550 In Patients With Moderate To Severe Ulcerative Colitis (OCTAVE)

Ulcerative Colitis

United States, Spain, Canada, Israel, Australia, Germany, Serbia, Japan, Denmark, France, Hungary, Poland, United Kingdom, Belgium, New Zealand, Netherlands, Austria, Colombia, Croatia, Czech Republic, Estonia, Italy, Latvia, Romania, Russian... and more
Pfizer

Terminated

Randomized Study Of Sunitinib Plus FOLFOX Versus Bevacizumab Plus FOLFOX In Metastatic Colorectal Cancer

Colorectal Neoplasms

United States, Denmark, Germany, Japan
Haruhiko Fukuda
Ministry of Health, Labour and Welfare, Japan

Completed

A Trial Comparing Adjuvant Oral UFT/LV to 5-FU/l-LV in Stage III Colorectal Cancer (JCOG-0205-MF)

Colorectal Neoplasms

Japan
BeiGene

Recruiting

A Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer

Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer

China, United States, Australia, Puerto Rico
Takeda

Completed

A Study to Evaluate Disease Control and Treatment Pattern in Participants With Moderate to Severe Inflammatory Bowel Disease (IBD) in Real Life Practice (INTENT)

Inflammatory Bowel Diseases | Crohn Disease | Colitis, Ulcerative

Russian Federation, Belarus, Kazakhstan
Pfizer

Terminated

A Study of Tofacitinib in Patients With Ulcerative Colitis in Stable Remission

Ulcerative Colitis

Spain, United States, Korea, Republic of, Serbia, Canada, Poland, Japan, France, New Zealand, South Africa, Germany, Slovakia, Hungary, Belgium, Czechia, Italy, Netherlands, Russian Federation, Ukraine, United Kingdom
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S1417CD Financial Impact Assessment Tool in Patients With Metastatic Colorectal Cancer

Stage IVA Colon Cancer | Stage IVA Rectal Cancer | Stage IVB Colon Cancer | Stage IVB Rectal Cancer

United States
Ferring Pharmaceuticals

Completed

To Evaluate the Efficacy and Safety of FE 999315 in Japanese Subjects With Mild to Moderate Active Ulcerative Colitis

Colitis, Ulcerative

Japan
Amgen

Completed

Comparison of Survival Benefit of Panitumumab With Supportive Care to Best Supportive Care Alone in Patients With Metastatic Colorectal Cancer

Metastatic Colorectal Cancer

Romania, Canada, Korea, Republic of, Philippines, Lithuania, Serbia, Latvia, Estonia, Greece, India, China, Croatia, Mexico, Malaysia, Chile, Brazil
AstraZeneca

Completed

Cediranib (AZD2171, RECENTIN™) in Addition to Chemotherapy in Patients With Untreated Metastatic Colorectal Cancer (HORIZON II)

Metastatic Colorectal Cancer

Brazil, Bulgaria, Czech Republic, Korea, Republic of, Poland, United Kingdom, Philippines, China, Germany, Hungary, Argentina, Taiwan, Switzerland, Australia, India
UCB BIOSCIENCES, Inc.
Pharmaceutical Research Associates

Completed

A Study to Assess the Safety and Efficacy of Lacosamide Versus Placebo (a Pill Without Active Medication) in Patients With Idiopathic Generalised Epilepsy Who Are Already Taking Anti-epileptic Medications (VALOR)

Epilepsy

United States, Australia, Belgium, Brazil, Bulgaria, China, Czechia, France, Germany, Hungary, Israel, Italy, Japan, Korea, Republic of, Mexico, Poland, Portugal, Romania, Russian Federation, Slovakia, Spain, Taiwan
Takeda

Completed

Safety and Efficacy Study of mFOLFOX6 + Panitumumab Combination Therapy and 5-FU/LV + Panitumumab Combination Therapy in Participants With Chemotherapy-naïve Unresectable Advanced Recurrent Colorectal Carcinoma (SAPPHIRE)

Colorectal Carcinoma

Japan
Sumitomo Pharma America, Inc.

Completed

A Study of Napabucasin (BBI-608) in Combination With FOLFIRI in Adult Patients With Previously Treated Metastatic Colorectal Cancer (CanStem303C)

Colorectal Cancer

United States, Canada, Spain, Australia, China, Hong Kong, Israel, Czechia, France, Japan, Belgium, Germany, Netherlands, Italy, Korea, Republic of, Singapore
AbbVie

Recruiting

Study to Assess Adverse Events, Change in Disease Activity, and How Oral Upadacitinib Moves Through the Body of Pediatric Participants With Moderately to Severely Active Ulcerative Colitis.

Ulcerative Colitis

United States, Japan, Spain, Korea, Republic of, Taiwan, Bulgaria, Italy, Poland, France, United Kingdom, Greece, New Zealand, Australia, Belgium, Israel, Hungary, Netherlands
Takeda

Completed

Phase III Study of MLN0002 (300 mg) in the Treatment of Ulcerative Colitis

Ulcerative Colitis

Japan
Bayer

Terminated

Colorectal Cancer Treated With Adjuvant Regorafenib Versus Placebo After Curative Treatment of Liver Metastases in a Randomized, Double-blind, Placebo-Controlled Phase-III STudy (COAST)

Colorectal Neoplasms

Belgium, France, Spain, China, United States, Canada, Germany, Portugal, Japan, Israel, United Kingdom, Italy, Australia, Brazil
Bayer

Completed

Patients With Metastatic Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard Therapy

Metastatic Colorectal Cancer

Belgium, Italy, Spain, Canada, Japan, Czech Republic, United States, Australia, France, Hungary, China, Germany, Israel, Netherlands, Turkey, Portugal, Brazil, Switzerland, Argentina
Pfizer
Arena is a wholly owned subsidiary of Pfizer

Completed

Etrasimod Dose-Ranging Versus Placebo as Induction Therapy Study in Adult Japanese Subjects With Moderately to Severely Active Ulcerative Colitis

Ulcerative Colitis

Japan
Nektar Therapeutics
Eli Lilly and Company

Terminated

A Study of LY3471851 in Adult Participants With Moderately to Severely Active Ulcerative Colitis (UC) (INSTRUCT-UC)

Colitis, Ulcerative

Australia, India, United States, Korea, Republic of, Hungary, United Kingdom, Japan, Argentina, Belgium, Brazil, Canada, China, Czechia, France, Georgia, Israel, Latvia, Poland, Romania, Russian Federation, Slovakia, Ukraine
NCIC Clinical Trials Group
Sumitomo Pharma Oncology, Inc.

Completed

BBI608 and Best Supportive Care vs Placebo and Best Supportive Care in Pretreated Advanced Colorectal Carcinoma

Colorectal Carcinoma

Canada, Australia, Japan
Novartis Pharmaceuticals

Recruiting

Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation (KontRASt-01)

Carcinoma, Non-Small-Cell Lung | Lung Cancer | Neoplasms, Lung | Pulmonary Neoplasms | Neoplasms, Pulmonary | Pulmonary Cancer | Cancer of Lung | Cancer of the Lung | KRAS G12C Mutant Solid Tumors | Carcinoma, Colorectal

United States, Japan, Australia, Germany, Italy, Spain, Canada, Denmark, Korea, Republic of, Taiwan, Belgium, Hong Kong, China, France, Singapore, Netherlands
Takeda

Recruiting

A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)

Crohn's Disease | Ulcerative Colitis

Belgium, Australia, Israel, United States, Hungary, Korea, Republic of, China, Canada, Croatia, Italy, Poland, Slovakia, United Kingdom, Japan, Greece

Clinical Trials on Chronic Back Pain in China

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Canada

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations